Second-generation antipsychotics: Cost-effectiveness, policy options, and political decision making

Robert A. Rosenheck, Douglas Leslie, Jalpa A. Doshi

Research output: Contribution to journalReview article

38 Citations (Scopus)

Abstract

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and other recent research suggest that second-generation antipsychotics other than clozapine may offer few, if any, advantages over first-generation antipsychotics, especially agents of intermediate potency. Thus the newer agents are not likely to generate sufficient benefit to justify their $11.5 billion annual cost. Policy approaches for containing drug costs are available and could improve cost-effectiveness by encouraging that second-generation antipsychotics be prescribed more selectively, such as only when clearly indicated. However, restrictions on either drug availability or physician choice are vigorously opposed by professional and consumer advocacy groups as well as by industry, and excessively restrictive approaches could unintentionally reduce access to beneficial treatments. Interventions that directly reduce second-generation antipsychotic prices would increase access for consumers but are inconsistent with broad opposition to government price regulation in the United States. High expenditures on these medications are thus likely to continue without concomitant gains for public health.

Original languageEnglish (US)
Pages (from-to)515-520
Number of pages6
JournalPsychiatric Services
Volume59
Issue number5
DOIs
StatePublished - May 1 2008

Fingerprint

Antipsychotic Agents
Cost-Benefit Analysis
Decision Making
Consumer Advocacy
Government Regulation
Drug Costs
Clozapine
Health Expenditures
Industry
Public Health
Clinical Trials
Physicians
Costs and Cost Analysis
Research
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

@article{1e64e68bc5644566acae36485a4d5a9f,
title = "Second-generation antipsychotics: Cost-effectiveness, policy options, and political decision making",
abstract = "The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and other recent research suggest that second-generation antipsychotics other than clozapine may offer few, if any, advantages over first-generation antipsychotics, especially agents of intermediate potency. Thus the newer agents are not likely to generate sufficient benefit to justify their $11.5 billion annual cost. Policy approaches for containing drug costs are available and could improve cost-effectiveness by encouraging that second-generation antipsychotics be prescribed more selectively, such as only when clearly indicated. However, restrictions on either drug availability or physician choice are vigorously opposed by professional and consumer advocacy groups as well as by industry, and excessively restrictive approaches could unintentionally reduce access to beneficial treatments. Interventions that directly reduce second-generation antipsychotic prices would increase access for consumers but are inconsistent with broad opposition to government price regulation in the United States. High expenditures on these medications are thus likely to continue without concomitant gains for public health.",
author = "Rosenheck, {Robert A.} and Douglas Leslie and Doshi, {Jalpa A.}",
year = "2008",
month = "5",
day = "1",
doi = "10.1176/appi.ps.59.5.515",
language = "English (US)",
volume = "59",
pages = "515--520",
journal = "Psychiatric Services",
issn = "1075-2730",
publisher = "American Psychiatric Association",
number = "5",

}

Second-generation antipsychotics : Cost-effectiveness, policy options, and political decision making. / Rosenheck, Robert A.; Leslie, Douglas; Doshi, Jalpa A.

In: Psychiatric Services, Vol. 59, No. 5, 01.05.2008, p. 515-520.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Second-generation antipsychotics

T2 - Cost-effectiveness, policy options, and political decision making

AU - Rosenheck, Robert A.

AU - Leslie, Douglas

AU - Doshi, Jalpa A.

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and other recent research suggest that second-generation antipsychotics other than clozapine may offer few, if any, advantages over first-generation antipsychotics, especially agents of intermediate potency. Thus the newer agents are not likely to generate sufficient benefit to justify their $11.5 billion annual cost. Policy approaches for containing drug costs are available and could improve cost-effectiveness by encouraging that second-generation antipsychotics be prescribed more selectively, such as only when clearly indicated. However, restrictions on either drug availability or physician choice are vigorously opposed by professional and consumer advocacy groups as well as by industry, and excessively restrictive approaches could unintentionally reduce access to beneficial treatments. Interventions that directly reduce second-generation antipsychotic prices would increase access for consumers but are inconsistent with broad opposition to government price regulation in the United States. High expenditures on these medications are thus likely to continue without concomitant gains for public health.

AB - The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and other recent research suggest that second-generation antipsychotics other than clozapine may offer few, if any, advantages over first-generation antipsychotics, especially agents of intermediate potency. Thus the newer agents are not likely to generate sufficient benefit to justify their $11.5 billion annual cost. Policy approaches for containing drug costs are available and could improve cost-effectiveness by encouraging that second-generation antipsychotics be prescribed more selectively, such as only when clearly indicated. However, restrictions on either drug availability or physician choice are vigorously opposed by professional and consumer advocacy groups as well as by industry, and excessively restrictive approaches could unintentionally reduce access to beneficial treatments. Interventions that directly reduce second-generation antipsychotic prices would increase access for consumers but are inconsistent with broad opposition to government price regulation in the United States. High expenditures on these medications are thus likely to continue without concomitant gains for public health.

UR - http://www.scopus.com/inward/record.url?scp=49749099137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49749099137&partnerID=8YFLogxK

U2 - 10.1176/appi.ps.59.5.515

DO - 10.1176/appi.ps.59.5.515

M3 - Review article

C2 - 18451007

AN - SCOPUS:49749099137

VL - 59

SP - 515

EP - 520

JO - Psychiatric Services

JF - Psychiatric Services

SN - 1075-2730

IS - 5

ER -